12,372 trials
Epilepsy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (TESAEs): Safety Population — 38; 4 Participants
GERD
Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…
Postoperative Pain
Primary: Visual Analogue Scale (VAS) in Resting Stage at 6hour (6hour±20 Minutes After Administration of First Dose) — 46.21; 45.48; 20.21; 19.94 units on a scale
Hypophosphatasia
Primary: Effect of Asfotase Alfa Treatment on Skeletal Manifestations of Hypophosphatasia (HPP) — 2.00 scores on a scale
Rheumatoid Arthritis
Primary: Safety: Change in DAS28-CRP Score From Baseline to Week 24 in Patients Treated With GP2015 and Patients Treated With Enbrel — -2.80; -2.73 scores on a scale
Major Depressive Disorder
Primary: Dose-dependent Differences in the BOLD Response to fMRI Tasks in the Amygdala — 0.20; 0.21; 0.23; 0.23 percent signal change — p=0.512
Hypogonadism
Primary: Number of Oral TU Treated Subjects Who Have a Total T Cavg in the Eugonadal Range of 252 to 907 ng/dL at Visit 7 — 145; 48 Participants
Overweight · Autism Spectrum Disorder
Primary: Change in Body Mass Index Z-score — 0.02; -0.08 16-wk change in BMI z-score
Moderate to Severe Palmoplantar Psoriasis
Primary: Percentages of Participants With Palmoplantar Investigator Global Assessmnet (ppIGA) 0 or 1 Response After 16 Weeks of Treatment — 22; 33.3; 1.5 Percentages of…
Influenza, Human
Primary: Number of Participants With Any Adverse Event (AE), Drug-related AE, Grade 3 and Grade 4 AE, Grade 3 and 4 Drug-related AE , AE Leading to Discontinuation of Study Drug…
Anemia of Chronic Kidney Disease
Primary: Percentage of Subjects Achieving an Increase in Hemoglobin of ≥1.0 g/dL at Any Time Point Between Baseline and the End of the 16-week Randomized Period — 61; 22…
Physical Frailty · Hip Fracture · Elective Hip Replacement
Primary: Mean Change in Total Lean Body Mass — 0.5; 2.3 kg — p=0.01
Spinal Muscular Atrophy
Primary: Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 — -1.0; 3.9 scores on a scale — p=0.0000001
HIV
Primary: Incidence of Treatment-Emergent Serious Adverse Events — 4.0; 0 percentage of participants
Alzheimer's Disease
Primary: Change in Cognition — 0.64; 0.55; 1.27 units on a scale — p=1.000